Fasıme Ozge AYGUN KAS

Fasıme Ozge AYGUN KAS

Auto-generated profile, based on publicly available information

Fasıme Ozge AYGUN KAS

Zonguldak Atatürk State Hospital, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2022 in Hitit Medical Journal
Verified
Journal Article
Closed access
DCDuygu Kayar Calili
Duygu Kayar Calili
NANurten Arslan
Nurten Arslan
ITIsmaıl TURKOZ
Ismaıl TURKOZ
GTGılman Tugce Tutkun
Gılman Tugce Tutkun
EGEmine Geçki̇l
Emine Geçki̇l
UGUmıt GEMICI
Umıt GEMICI
Aim: We aimed to compare RT-PCR positive and RT-PCR negative patients with radiologically confirmed COVID-19 pneumonia admitted to the intensive care unit (ICU) in terms of outcome and laboratory results in the inflammation process. Material / Method: Patients who were admitted to the ICU due to respiratory failure and had typical COVID-19 pneumonia findings on thorax tomography were included in the study. Patients were grouped as RT-PCR negative and RT-PCR positive. Groups were compared for descriptive and laboratory characteristics, treatments, length of stay and outcome. Results: Lactate, D-dimer levels, and leukocyte, neutrophil counts of the RT-PCR positive group were lower than the other group (p

1 January 2025 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
PDF file
MTMehmet Ali Tüz
Mehmet Ali Tüz
ITİsMail Türköz
İsMail Türköz
OAOytun Aydogan
Oytun Aydogan
EGEmine Gencer
Emine Gencer
FAFadime Özge Aygün-Kaş
Fadime Özge Aygün-Kaş
HTHande İdIl Tüz
Hande İdIl Tüz
Most SARS-CoV-2 infections are asymptomatic or cause only mild illness, but severe respiratory disease can develop, sometimes requiring oxygen support. Immunopathological damage resulting from an abnormal inflammatory response in patients with severe disease is known to be the main determinant of disease outcome. Studies show that anti-inflammatory therapies work best when used before widespread immunopathological damage has occurred. Similarly, it was thought that intravenous immunoglobulin (IVIG)—holding multiple immunomodulatory effects—would provide clinically favorable results, but recent studies suggest otherwise. Still, the literature shows few studies evaluating the efficacy of IVIG according to the time of administration and there are no studies comparing it with established treatments, such as tocilizumab. In this study, we aimed to evaluate the effects of early administration of tocilizumab and IVIG on clinical outcome in patients with severe COVID-19. Patients with progressive clinical and laboratory deterioration who received tocilizumab or IVIG between 07/2020 and 10/2020 in a public hospital ward were retrospectively evaluated. A total of 74 patients were identified, of whom 29 (39%) received IVIG only and 26 (35%) received tocilizumab only. As a result, patients with severe COVID-19 who received IVIG in early stages of the disease did not have better clinical outcomes regarding mortality, length of hospital stay and ICU admission compared to those who received tocilizumab. Moreover, there is no data to support the use of IVIG in COVID-19 patients with severe disease, as it is associated with more severe side effects and is more expensive than tocilizumab.